// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Prevention and management of Deep Brain Stimulation (DBS) surgical site infections (SSI) – multicentre survey of UK practice.

S. Perides - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Protein aggregation and calcium dysregulation are the earliest hallmarks of synucleinopathy in enriched iPSC-derived human midbrain dopaminergic neurons

G. Virdi - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Real-world sit-to-stand evaluation

C. Morgan - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Remote keyboard tapping: potential signatures of early motor dysfunction in isolated REM sleep behaviour disorder

C. Simonet - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Screening of autistic traits in people with functional neurological disorders

B. Gonzalez-Herrero - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Autism

N/A

Sleep in adult-onset idiopathic focal cervical dystonia (AOIFCD): an evaluation using self-reported and accelerometer derived measures

G. Bailey - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Cervical dystonia

N/A

Socio-economic factors influencing Parkinson’s disease self-management

L. Ambrosio - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Subgroup analyses by Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) of patients treated with levodopa inhalation powder 84mg or placebo to treat OFF symptoms in patients with Parkinson’s disease (PD)

D. Grosset - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Levodopa

Diagnostic accuracy of dopamine SPECT in degenerative parkinsonism compared to neuropathological diagnosis.

A. Hastings - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Dopamine hydrochloride

Progress of the UK Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial

A. Bamford - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Rivastigmine

Hematuria and proteinuria with respiratory illnesses: IgA nephropathy vs. C3 glomerulopathy?

Kelly Liang - National Kidney Foundation (NKF) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

C3 glomerulopathy

Lisinopril

Finerenone and chronic kidney disease outcomes in Black patients with type 2 diabetes: A FIDELITY analysis

John M. Flack - National Kidney Foundation (NKF) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Chronic kidney disease

Finerenone

Comparing characteristics of patients with CKD and hyperkalaemia with and without a diagnostic code for hyperkalaemia: a report from the DISCOVER CKD retrospective cohort

Lucy Ambrose - National Kidney Foundation (NKF) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Non-dialysis-dependent chronic kidney disease

N/A

Evaluating clinical outcomes in patients (pts) with CKD with rapid and non-rapid eGFR decline: a report from the DISCOVER CKD retrospective cohort

H Heerspink - National Kidney Foundation (NKF) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Comparing characteristics of patients (pts) with CKD and hyperkalemia (HK) with and without a diagnostic (Dx) code for HK: a report from the DISCOVER CKD retrospective cohort

C Pollock - National Kidney Foundation (NKF) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Non-dialysis-dependent chronic kidney disease

N/A

Reduction of Pruritus by Difelikefalin Correlates With Reductions in Markers for Pruritus and Inflammation in Subjects Undergoing Hemodialysis

Shayan Shirazian - National Kidney Foundation (NKF) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Difelikefalin

Association of wnt signalling with metachronous colonic polyp risk.

Joanne Edwards - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Aluminum hydroxide / magnesium hydroxide / simethicone

Significance of alterations in DNA damage repair (DDR) genes in advanced biliary cancers (ABCs) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 trial.

Angela Lamarca - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Oxaliplatin

Do nonoperative modality (NOM) treatments of rectal cancer compromise the chance of cure? Final surgical salvage results from OPERA phase 3 randomised trial (NCT02505750).

Arthur Sun Myint - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Capecitabine

Relevance of adjuvant chemotherapy in elderly patients with low rectal tumors.

Sola Adeleke - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved